Two Sigma Investments LP lessened its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 70.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 24,987 shares of the specialty pharmaceutical company's stock after selling 59,580 shares during the period. Two Sigma Investments LP's holdings in Supernus Pharmaceuticals were worth $904,000 at the end of the most recent quarter.
A number of other institutional investors also recently bought and sold shares of the stock. Barclays PLC raised its stake in shares of Supernus Pharmaceuticals by 88.3% in the third quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company's stock valued at $3,393,000 after acquiring an additional 51,005 shares during the period. Janney Montgomery Scott LLC bought a new position in Supernus Pharmaceuticals during the 4th quarter valued at about $211,000. KBC Group NV raised its position in Supernus Pharmaceuticals by 53.1% in the 4th quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company's stock worth $97,000 after purchasing an additional 929 shares during the period. Empowered Funds LLC bought a new stake in Supernus Pharmaceuticals in the fourth quarter worth about $1,498,000. Finally, Newbridge Financial Services Group Inc. bought a new stake in Supernus Pharmaceuticals in the fourth quarter worth about $72,000.
Supernus Pharmaceuticals Stock Down 0.0%
SUPN traded down $0.01 on Tuesday, reaching $33.26. 388,855 shares of the company traded hands, compared to its average volume of 476,650. The company has a market cap of $1.86 billion, a P/E ratio of 31.08 and a beta of 0.71. Supernus Pharmaceuticals, Inc. has a one year low of $25.53 and a one year high of $40.28. The firm has a fifty day simple moving average of $31.97 and a two-hundred day simple moving average of $34.42.
Wall Street Analysts Forecast Growth
A number of research firms have recently commented on SUPN. Wall Street Zen raised Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, May 16th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $36.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.
View Our Latest Report on Supernus Pharmaceuticals
About Supernus Pharmaceuticals
(
Free Report)
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.
Featured Stories
Before you consider Supernus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Supernus Pharmaceuticals wasn't on the list.
While Supernus Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
